Cleared Traditional

K252429 - Vektor Computational ECG Mapping System...

K252429 is an FDA 510(k) clearance for Vektor Computational ECG Mapping System..., manufactured by Vektor Medical, Inc.. The device is a Class 2 Cardiovascular device with product code DQK cleared through the Traditional 510(k) pathway after a 125-day FDA review.

K252429 · Vektor Medical, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2025
Decision
125d
Days
Class 2
Risk

K252429 is an FDA 510(k) clearance for the Vektor Computational ECG Mapping System (vMap®). Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Vektor Medical, Inc. (San Diego, US). The FDA issued a Cleared decision on December 4, 2025 after a review of 125 days - within the typical 510(k) review window.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Cardiovascular review framework, consistent with the majority of Class II 510(k) submissions.

View all Vektor Medical, Inc. devices

FDA 510(k) Submission Details - K252429

510(k) Number K252429 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 01, 2025
Decision Date December 04, 2025
Days to Decision 125 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
At panel average
Panel avg: 125d · This submission: 125d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

DQK Device Classification - Class 2, Special Controls

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 269
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K252429.
STAR Apollo™ Mapping System
K253733 · Rhythm AI, Ltd. · Dec 2025
HemoSphere Alta Advanced Monitoring Platform (ALTAALL1
K252533 · Edwards Lifesciences · Dec 2025
DeepRhythmAI
K253141 · Medicalgorithmics S.A. · Dec 2025
CoroFlow Cardiovascular System
K252238 · Coroventis Research AB · Oct 2025
LumiGuide Equipment R2.1
K252645 · Philips Medical Systems Nederland B.V. · Oct 2025
HemoSphere Stream Module
K253034 · Edwards Lifesciences · Oct 2025